Abstract: The present invention refers to a liposome comprising: a) a phospholipid; b) cholesterol (chol); c) a conjugate comprising a cholesterol moiety, a polyethylene glycol (PEG) moiety and a peptide moiety comprising a RGD sequence, wherein the PEG moiety is covalently attached to the cholesterol moiety by one end via a bond of the type alkyl ether and is covalently attached to the peptide moiety comprising the RGD sequence by the other end: d) a non-lipid cationic surfactant present in a percentage of less than 30% mol in respect to the total mol of the components of the liposome a), b), c) and d); and e) alpha-galactosidase (GLA) enzyme present in a ratio of micrograms of GLA in respect to the total milligrams of the components of the liposome a), b), c) and d) of between and including 2 to 35. It also refers to a pharmaceutical composition that comprises it and to the liposome or the pharmaceutical composition for use as a medicament, in particular for use in the treatment of Fabry disease.

Abstract: The present invention discloses a hydrogel comprising a functionalized PEG multi-arm star polymer covalently combined with maleimide-functionalized low molecular weight heparin, further comprising at least one positively charged immune molecule, a method for producing this hydrogel and its use in T cell culture for immunotherapies. Furthermore, the invention relates to a bioink and its use in 3D-(bio)-printing.

Abstract: The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.

Abstract: The present invention refers to a nanovesicle comprising a sterol and a non-lipid cationic surfactant, for example myristalkonium chloride, wherein the sterol comprises DC-cholesterol. It also refers to a pharmaceutical composition that comprises it and its uses as a delivery system and as a bioimaging and theranostic tool. Furthermore, it also refers to the nanovesicle or the pharmaceutical composition for use as a medicament, in particular for use in the treatment of cancer.

Abstract: The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.

Abstract: The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.

Abstract: The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.

Abstract: The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.

Abstract: The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.

Abstract: The invention provides a novel method for obtaining solid micro- or nanoparticles with a homogeneous structure. A method is provided for obtaining solid micro- or nanoparticles with a homogeneous structure having a particle size of less than 10 ?m where the processed solid compound has the natural, crystalline, amorphous, polymorphic and other features associated with the starting compound. In accordance with the invention a method which also makes it possible to obtain solid micro- or nanoparticles with a substantially spheroidal morphology is provided.

Abstract: The invention provides a novel method for obtaining solid micro- or nanoparticles with a homogeneous structure. A method is provided for obtaining solid micro- or nanoparticles with a homogeneous structure having a particle size of less than 10 ?m where the processed solid compound has the natural, crystalline, amorphous, polymorphic and other features associated with the starting compound. In accordance with the invention a method which also makes it possible to obtain solid micro- or nanoparticles with a substantially spheroidal morphology is provided.

Abstract: The present invention relates to an isolated inclusion body comprising a polypeptide, characterised in that such inclusion body is in particulate form. The present invention also refers to a bacterial cell comprising said inclusion body. The present invention additionally refers to a composition comprising said inclusion body and a eukaryotic cell. The present invention moreover refers to a composition comprising said inclusion body and animal or plant tissue. The present invention furthermore refers to the uses of said inclusion body as medicaments and cell-proliferation stimulators and tissue regenerators.

Abstract: The invention is characterized in that it comprises a truncated contact lens (1), whose truncation plane is parallel to the base of said contact lens, and a polymeric nanocomposite material (2) centrally disposed and attached to the perimeter of the truncated area, said material being sensitive to pressure changes, biocompatible and transparent, and including contact electrodes (3), and in that it also comprises means for transmitting IOP measurement data to an external system. The invention also relates to a method for measuring IOP using said lens comprising: i) placing said sensor contact lens in the eye to determine its intraocular pressure; ii) providing a direct current value between external electrodes; iii) ?V measurement between internal electrodes; and iv) identifying whether the value obtained is outside the linear response, expressed in changes of resistivity, of the polymeric nanocomposite material. The invention also relates to a telemetry system comprising said lens.

Abstract: The invention relates to a method for obtaining micro- and nanodisperse systems. In particular, it relates to a method that allows said systems, such as liposomes, emulsions and suspensions, to be obtained with a size of less than 50 ?m, and preferably less than 1 ?m, and with improved stability properties over time, which includes the stages of a) Dissolving or suspending a compound C in a fluid A, to obtain a mixture AC, in the form of a solution or dispersion; b) Thermostatising said mixture AC to a temperature of between ?50° C. and 200° C.; c) Adding a fluid B to mixture AC until a pressure P is obtained; and it is characterised in that in said stage (c) formation of the solution AB occurs and because it includes, d) Reducing the pressure of solution AB to a pressure lower than or equal to 100 bars, and then e) Adding a fluid E, in which fluid A is miscible and in which compound C is partially or totally insoluble at atmospheric pressure, with said fluid E acting as a crystallisation interruption agent.

Abstract: Disclosed herein are embodiment relating to a methods of obtaining a functionalized porous or fibrous solid substrate with the chemical and/or physical properties of a nano-structured molecular or polymer chemical compound that contains it. In accordance with some example embodiments, the properties of the starting substrate may be modified to obtain a new functionalized substrate. The new substrate may have various applications, such as, for example, an optical- and/or fluorescent-type chemical sensor, as a chemical sequestrator, or as a modifier of the properties of a surface, making it, for example, superhydrophobic.

Abstract: The invention is characterised in that it has a layer of organic material sensitive to changes in pressure, voltage, deformation, gases and/or temperature; wherein said organic layer consists of at least one conductive salt or complex including a molecule A and a dopant D, said molecule A being an electron donor or acceptor organic molecule or macromolecule capable of forming a conductive salt or complex, which without doping is not conductive, and with the presence of dopant D becomes a compound that is donor or acceptor of electrons and capable of forming conductive salt or complex with the molecule or macromolecule A; and a base substrate, in close contact with said layer of organic material. The sensor device is useful in molecular electronics or plastic electronics, in particular, in the field of organic sensors.

Abstract: The invention relates to a chemical method that enables the direct design of a pattern on an organic substrate having semiconductor-, superconductor- or metallic-type conducting properties. The invention also relates to the organic material thus obtained, which is intended for use in electronic devices, such as resistors, capacitors, transistors, sensors or electrodes among others, or for use in other applications requiring a determined pattern of conductor or semiconductor zones and less-conducting, non-conducting or insulating zones.

Abstract: A method for precipitation of finely divided solid particles comprising a) Dissolving a compound C in a fluid A to provide a solution A; b) Thermostatization of said solution A to a temperature ranging between ?50°0 C. and 200° C.; c) Adding a fluid B to said solution A until a pressure P is obtained, characterized in that said fluid B at a pressure P is miscible with said solution A and acts as a co-solvent to form a solution AB; d) Adding an inert gas to solution AB so as to maintain the pressure P; and e) Reducing the pressure of said solution AB so as to produce the precipitation of said compound C, and wherein the method permits particles of average size less than 20 ?m, with a narrow distribution ranging between 1 and 100 ?m, from a solution, and not a mix, that contains the compound C precipitated.

Abstract: Comprises a) dissolving a compound C in a fluid A to provide a solution A; b) Thermostatization of said solution A to a temperature ranging between −50° C. and 200° C.; c) Adding a fluid B to said solution A until a pressure P is obtained, and is characterized in that said fluid B at a pressure P is miscible with said solution A, and acts as a co-solvent to form a solution AB; and d) Reduce the pressure of said solution AB so as to produce the precipitation of said compound C.